Table of Contents
Thrombosis
Volume 2012, Article ID 720254, 8 pages
http://dx.doi.org/10.1155/2012/720254
Review Article

Do Aspirin and Other Antiplatelet Drugs Reduce the Mortality in Critically Ill Patients?

1Center for Sepsis Control and Care, Jena University Hospital, Erlanger Allee 101, 07740 Jena, Germany
2Department of Anesthesiology and Intensive Care Medicine, Center for Sepsis Control and Care, University Hospital Jena, Bachstraße 18, Gebäude 12, Eingang A, 07743 Jena, Germany

Received 6 June 2011; Accepted 3 October 2011

Academic Editor: Jeanine M. Walenga

Copyright © 2012 Wolfgang Lösche et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Levi, “Platelets in sepsis,” Hematology, vol. 10, supplement 1, pp. 129–131, 2005. View at Google Scholar
  2. J. L. Vincent, A. Yagushi, and O. Pradier, “Platelet function in sepsis,” Critical Care Medicine, vol. 30, supplement 5, pp. S313–S317, 2002. View at Google Scholar · View at Scopus
  3. J. N. Katz, K. P. Kolappa, and R. C. Becker, “Beyond thrombosis: the versatile platelet in critical illness,” Chest, vol. 139, no. 3, pp. 658–668, 2011. View at Google Scholar
  4. S. Akca, P. Haji-Michael, A. De Mendonça, P. Suter, M. Levi, and J. L. Vincent, “Time course of platelet counts in critically ill patients,” Critical Care Medicine, vol. 30, no. 4, pp. 753–756, 2002. View at Google Scholar · View at Scopus
  5. D. Moreau, J. F. Timsit, A. Vesin et al., “Platelet count decline: an early prognostic marker in critically III patients with prolonged ICU stays,” Chest, vol. 131, no. 6, pp. 1735–1741, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. M. Vandijck, S. I. Blot, J. J. De Waele, E. A. Hoste, K. H. Vandewoude, and J. M. Decruyenaere, “Thrombocytopenia and outcome in critically ill patients with bloodstream infection,” Heart and Lung, vol. 39, no. 1, pp. 21–26, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Gawaz, S. Fateh-Moghadam, G. Pilz, H. J. Gurland, and K. Werdan, “Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure,” European Journal of Clinical Investigation, vol. 25, no. 11, pp. 843–851, 1995. View at Google Scholar · View at Scopus
  8. H. Ogura, T. Kawasaki, H. Tanaka et al., “Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis,” Journal of Trauma, vol. 50, no. 5, pp. 801–809, 2001. View at Google Scholar · View at Scopus
  9. S. Russwurm, J. Vickers, A. Meier-Hellmann et al., “Platelet and leukocyte activation correlate with the severity of septic organ dysfunction,” Shock, vol. 17, no. 4, pp. 263–268, 2002. View at Google Scholar · View at Scopus
  10. C. L. Bockmeyer, R. A. Claus, U. Budde et al., “Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor,” Haematologica, vol. 93, no. 1, pp. 137–140, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. A. Claus, C. L. Bockmeyer, M. Sossdorf, and W. Lösche, “The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure?” Current Molecular Medicine, vol. 10, no. 2, pp. 236–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. A. K. Hovinga, S. Zeerleder, P. Kessler et al., “ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock,” Journal of Thrombosis and Haemostasis, vol. 5, no. 11, pp. 2284–2290, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. T. N. Bongers, M. Emonts, M. P. M. De Maat et al., “Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1181–1187, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. G. Andonegui, S. M. Kerfoot, K. McNagny, K. V. J. Ebbert, K. D. Patel, and P. Kubes, “Platelets express functional Toll-like receptor-4,” Blood, vol. 106, no. 7, pp. 2417–2423, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. Zhang, J. Han, E. J. Welch et al., “Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway,” Journal of Immunology, vol. 182, no. 12, pp. 7997–8004, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. T. Brown and T. M. McIntyre, “Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1beta-rich microparticles,” Journal of Immunology, vol. 186, no. 9, pp. 5489–5496, 2011. View at Google Scholar
  17. M. Czabanka, C. Peter, E. Martin, and A. Walther, “Microcirculatory endothelial dysfunction during endotoxemia—insights into pathophysiology, pathologic mechanisms and clinical relevance,” Current Vascular Pharmacology, vol. 5, no. 4, pp. 266–275, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Secor, F. Li, C. G. Ellis et al., “Impaired microvascular perfusion in sepsis requires activated coagulation and P-selectin-mediated platelet adhesion in capillaries,” Intensive Care Medicine, vol. 36, no. 11, pp. 1928–1934, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. K. Tyml, “Critical role for oxidative stress, platelets, and coagulation in capillary blood flow impairment in sepsis,” Microcirculation, vol. 18, no. 2, pp. 152–162, 2011. View at Google Scholar
  20. C. L. Bockmeyer, P. A. Reuken, T. P. Simon et al., “ADAMTS13 activity is decreased in a septic porcine model. Significance for glomerular thrombus deposition,” Thrombosis and Haemostasis, vol. 105, no. 1, pp. 145–153, 2011. View at Google Scholar
  21. H. D. Flad and E. Brandt, “Platelet-derived chemokines: pathophysiology and therapeutic aspects,” Cellular and Molecular Life Sciences, vol. 67, no. 14, pp. 2363–2386, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. S. Weyrich and G. A. Zimmerman, “Platelets: signaling cells in the immune continuum,” Trends in Immunology, vol. 25, no. 9, pp. 489–495, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. R. Steinhubl, “Platelets as mediators of inflammation,” Hematology/Oncology Clinics of North America, vol. 21, no. 1, pp. 115–121, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. R. L. Gear and D. Camerini, “Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense,” Microcirculation, vol. 10, no. 3-4, pp. 335–350, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. W. Semple and J. Freedman, “Platelets and innate immunity,” Cellular and Molecular Life Sciences, vol. 67, no. 4, pp. 499–511, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. S. S. Smyth, R. P. Mcever, A. S. Weyrich et al., “Platelet functions beyond hemostasis,” Journal of Thrombosis and Haemostasis, vol. 7, no. 11, pp. 1759–1766, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. I. B. Peerschke, W. Yin, and B. Ghebrehiwet, “Platelet mediated complement activation,” Advances in Experimental Medicine and Biology, vol. 632, pp. 81–91, 2008. View at Google Scholar · View at Scopus
  28. E. I. Peerschke, W. Yin, and B. Ghebrehiwet, “Complement activation on platelets: implications for vascular inflammation and thrombosis,” Molecular Immunology, vol. 47, no. 13, pp. 2170–2175, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. Wiesner and A. Vilcinskas, “Antimicrobial peptides: the ancient arm of the human immune system,” Virulence, vol. 1, no. 5, pp. 440–464, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. L. T. Nguyen, P. H. Kwakman, D. I. Chan et al., “Exploring platelet chemokine antimicrobial activity: nuclear magnetic resonance backbone dynamics of nap-2 and tc-1,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 2074–2083, 2011. View at Google Scholar
  31. S. R. Clark, A. C. Ma, S. A. Tavener et al., “Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood,” Nature Medicine, vol. 13, no. 4, pp. 463–469, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. F. Setzer, V. Oberle, M. Bläss et al., “Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study,” Platelets, vol. 17, no. 8, pp. 571–576, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. J. Winning, J. Neumann, M. Kohl et al., “Antiplatelet drugs and outcome in mixed admissions to an intensive care unit,” Critical Care Medicine, vol. 38, no. 1, pp. 32–37, 2010. View at Publisher · View at Google Scholar · View at PubMed
  34. X. Bosch, J. Marrugat, and J. Sanchis, “Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes,” Cochrane Database of Systematic Reviews, no. 9, Article ID CD002130, 2010. View at Google Scholar
  35. M. W. Behan, D. P. Chew, and P. E. Aylward, “The role of antiplatelet therapy in the secondary prevention of coronary artery disease,” Current Opinion in Cardiology, vol. 25, no. 4, pp. 321–328, 2010. View at Publisher · View at Google Scholar · View at PubMed
  36. T. S. Field and O. R. Benavente, “Current status of antiplatelet agents to prevent stroke,” Current Neurology and Neuroscience Reports, vol. 11, no. 1, pp. 6–14, 2011. View at Publisher · View at Google Scholar · View at PubMed
  37. F. Catella-Lawson, M. P. Reilly, S. C. Kapoor et al., “Cyclooxygenase inhibitors and the antiplatelet effects of aspirin,” The New England Journal of Medicine, vol. 345, no. 25, pp. 1809–1817, 2001. View at Publisher · View at Google Scholar · View at PubMed
  38. R. A. Chaer, J. A. Graham, and L. Mureebe, “Platelet function and pharmacologic inhibition,” Vascular and Endovascular Surgery, vol. 40, no. 4, pp. 261–267, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. A. J. Ansara, S. A. Nisly, S. A. Arif, J. M. Koehler, and S. T. Nordmeyer, “Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature,” Annals of Pharmacotherapy, vol. 44, no. 5, pp. 851–862, 2010. View at Publisher · View at Google Scholar · View at PubMed
  40. J. Herlitz, P. P. Tóth, and J. Næsdal, “Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation,” American Journal of Cardiovascular Drugs, vol. 10, no. 2, pp. 125–141, 2010. View at Google Scholar
  41. A. Lanas, “Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice,” Expert Opinion on Drug Safety, vol. 10, no. 1, pp. 45–54, 2011. View at Publisher · View at Google Scholar · View at PubMed
  42. S. Shakib, “Aspirin for primary prevention: do potential benefits outweigh the risks?” Internal Medicine Journal, vol. 39, no. 6, pp. 401–407, 2009. View at Publisher · View at Google Scholar · View at PubMed
  43. A. D. Michelson, “New P2Y12 antagonists,” Current Opinion in Hematology, vol. 16, no. 5, pp. 371–377, 2009. View at Publisher · View at Google Scholar · View at PubMed
  44. M. Cattaneo, “The platelet P2Y receptor for adenosine diphosphate: congenital and drug-induced defects,” Blood, vol. 117, no. 7, pp. 2102–2112, 2011. View at Google Scholar
  45. P. A. Gurbel, D. J. Kereiakes, and U. S. Tantry, “Ticagrelor for the treatment of arterial thrombosis,” Expert Opinion on Pharmacotherapy, vol. 11, no. 13, pp. 2251–2259, 2010. View at Publisher · View at Google Scholar · View at PubMed
  46. S. A. Mousa, W. P. Jeske, and J. Fareed, “Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist,” Methods in Molecular Biology, vol. 663, pp. 221–228, 2010. View at Publisher · View at Google Scholar
  47. A. W. J. Van't Hof and M. Valgimigli, “Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban,” Drugs, vol. 69, no. 1, pp. 85–100, 2009. View at Publisher · View at Google Scholar · View at PubMed
  48. L. Bolognese, “The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes,” Current Medical Research and Opinion, vol. 23, no. 6, pp. 1217–1226, 2007. View at Publisher · View at Google Scholar · View at PubMed
  49. H. Horiuchi, “Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems,” Annals of Medicine, vol. 38, no. 3, pp. 162–172, 2006. View at Publisher · View at Google Scholar · View at PubMed
  50. P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men,” The New England Journal of Medicine, vol. 336, no. 14, pp. 973–979, 1997. View at Publisher · View at Google Scholar
  51. S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J. M. Herbert, and T. Lüscher, “Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease,” Vascular Medicine, vol. 12, no. 2, pp. 113–122, 2007. View at Publisher · View at Google Scholar
  52. J. Graff, S. Harder, O. Wahl, E. H. Scheuermann, and J. Gossmann, “Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers,” Clinical Pharmacology and Therapeutics, vol. 78, no. 5, pp. 468–476, 2005. View at Publisher · View at Google Scholar · View at PubMed
  53. J. B. Muhlestein, “Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients,” Thrombosis and Haemostasis, vol. 103, no. 1, pp. 71–82, 2010. View at Publisher · View at Google Scholar · View at PubMed
  54. I. Ikonomidis, F. Andreotti, E. Economou, C. Stefanadis, P. Toutouzas, and P. Nihoyannopoulos, “Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin,” Circulation, vol. 100, no. 8, pp. 793–798, 1999. View at Google Scholar
  55. J. R. Fletcher, “Prostaglandin synthetase inhibitors in endotoxin or septic shock—a review,” Advances in Shock Research, vol. 10, pp. 9–14, 1983. View at Google Scholar
  56. P. S. Rao, D. Cavanagh, and L. W. Gaston, “Endotoxic shock in the primate: effects of aspirin and dipyridamole administration,” American Journal of Obstetrics and Gynecology, vol. 140, no. 8, pp. 914–922, 1981. View at Google Scholar
  57. U. Schaper, G. Lueddeckens, W. Forster, and D. W. Scheuch, “Inhibition of lipoxygenase (LOX) or of cyclooxygenase (COX) improves survival of rats in endotoxin shock,” Biomedica Biochimica Acta, vol. 47, no. 10-11, pp. S282–S285, 1988. View at Google Scholar
  58. Y. Ohtaki, H. Shimauchi, T. Yokochi, H. Takada, and Y. Endo, “In vivo platelet response to lipopolysaccharide in mice: proposed method for evaluating new antiplatelet drugs,” Thrombosis Research, vol. 108, no. 5-6, pp. 303–309, 2002. View at Publisher · View at Google Scholar
  59. L. Zhao, Y. Ohtaki, K. Yamaguchi et al., “LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system,” Blood, vol. 100, no. 9, pp. 3233–3239, 2002. View at Publisher · View at Google Scholar · View at PubMed
  60. F. B. Taylor, B. S. Coller, A. C. K. Chang et al., “7e3 f(ab′)2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli,” Blood, vol. 89, no. 11, pp. 4078–4084, 1997. View at Google Scholar
  61. Q. Pu, E. Wiel, D. Corseaux et al., “Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock,” Critical Care Medicine, vol. 29, no. 6, pp. 1181–1188, 2001. View at Google Scholar
  62. A. Walther, M. Czabanka, M. M. Gebhard, and E. Martin, “Glycoprotein IIB/IIIA-inhibition and microcirculatory alterations during experimental endotoxemia—an intravital microscopic study in the rat,” Microcirculation, vol. 11, no. 1, pp. 79–88, 2004. View at Publisher · View at Google Scholar
  63. V. Evangelista, S. Manarini, G. Dell'Elba et al., “Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation,” Thrombosis and Haemostasis, vol. 94, no. 3, pp. 568–577, 2005. View at Publisher · View at Google Scholar
  64. V. Evangelista, G. Dell'Elba, N. Martelli et al., “Anti-inflammatory effects of clopidogrel in the mouse,” Journal of Thrombosis and Haemostasis, vol. 5, supplement 2, p. P-M-283, 2007. View at Google Scholar
  65. J. Winning, J. Reichel, Y. Eisenhut et al., “Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms,” Platelets, vol. 20, no. 1, pp. 50–57, 2009. View at Publisher · View at Google Scholar · View at PubMed
  66. M. Seidel, J. Winning, R. A. Claus, M. Bauer, and W. Lösche, “Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis,” Journal of Thrombosis and Haemostasis, vol. 7, no. 6, pp. 1030–1031, 2009. View at Publisher · View at Google Scholar · View at PubMed
  67. S. Hagiwara, H. Iwasaka, A. Hasegawa et al., “Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model,” Shock, vol. 35, no. 3, pp. 289–292, 2011. View at Publisher · View at Google Scholar · View at PubMed
  68. X. Tu, X. Chen, Y. Xie et al., “Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury,” Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 77–83, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. K. Schrör, “Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis,” Seminars in Thrombosis and Hemostasis, vol. 23, no. 4, pp. 349–356, 1997. View at Google Scholar · View at Scopus
  70. R. F. Storey, “Biology and pharmacology of the platelet P2Y12 receptor,” Current Pharmaceutical Design, vol. 12, no. 10, pp. 1255–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Christensen, R. W. Thomsen, M. B. Johansen et al., “Preadmission statin use and one-year mortality among patients in intensive care—a cohort study,” Critical Care, vol. 14, no. 2, p. R29, 2010. View at Google Scholar · View at Scopus
  72. I. Kouroumichakis, N. Papanas, S. Proikaki, P. Zarogoulidis, and E. Maltezos, “Statins in prevention and treatment of severe sepsis and septic shock,” European Journal of Internal Medicine, vol. 22, no. 2, pp. 125–133, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. H. R. O'Neal Jr., T. Koyama, E. A. Koehler et al., “Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome,” Critical Care Medicine, vol. 39, no. 6, pp. 1343–1359, 2011. View at Google Scholar
  74. S. Janda, A. Young, J. M. FitzGerald, M. Etminan, and J. Swiston, “The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis,” Journal of Critical Care, vol. 25, no. 4, pp. 656.e7–656.e22, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. G. C. Makris, G. Geroulakos, M. C. Makris, D. P. Mikhailidis, and M. E. Falagas, “The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective,” Expert Opinion on Investigational Drugs, vol. 19, no. 7, pp. 809–814, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. D. Viasus, C. Garcia-Vidal, F. Gudiol, and J. Carratalà, “Statins for community-acquired pneumonia: current state of the science,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 29, no. 2, pp. 143–152, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. J. M. Erlich, D. S. Talmor, R. Cartin-Ceba, and D. J. Kor, “Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study,” Chest, vol. 139, no. 2, pp. 289–295, 2011. View at Google Scholar
  78. D. J. Kor, J. Erlich, M. N. Gong et al., “Association of prehospitalization aspirin therapy and acute lung injury: Results of a multicenter international observational study of at-risk patients,” Critical Care Medicine, vol. 39, no. 22, pp. 2393–2400, 2011. View at Publisher · View at Google Scholar · View at PubMed
  79. G. J. Blake and P. M. Ridker, “Inflammatory bio-markers and cardiovascular risk prediction,” Journal of Internal Medicine, vol. 252, no. 4, pp. 283–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Steffens and F. Mach, “Inflammation and atherosclerosis,” Herz, vol. 29, no. 8, pp. 741–748, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. H. Loppnow, K. Werdan, and M. Buerke, “Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms,” Innate Immunity, vol. 14, no. 2, pp. 63–87, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. C. I. Vardavas and D. B. Panagiotakos, “The causal relationship between passive smoking and inflammation on the development of cardiovascular disease: a review of the evidence,” Inflammation and Allergy—Drug Targets, vol. 8, no. 5, pp. 328–333, 2009. View at Google Scholar · View at Scopus
  83. P. G. Chassot, A. Delabays, and D. R. Spahn, “Perioperative use of anti-platelet drugs,” Best Practice and Research, vol. 21, no. 2, pp. 241–256, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. E. Hijazi, “Aspirin does dot increase bleeding and allogeneic blood transfusion in coronary artery surgery,” Thoracic and Cardiovascular Surgery, vol. 59, no. 7, pp. 421–424, 2011. View at Google Scholar
  85. G. Kotsovolis, G. Komninos, A. Kyrgidid, and D. Papadimitriou, “Preoperative withdrawal of antiplatelet treatment in lower limb vascular patients prior to surgical management under epidural or spinal anaesthesia: an evidence based approach and systematic review,” International Angiology, vol. 29, no. 6, pp. 475–481, 2010. View at Google Scholar
  86. P. F. Dineen, R. J. Curtin, and J. A. Harty, “A review of the use of common antiplatelet agents in orthopaedic practice,” Journal of Bone and Joint Surgery B, vol. 92, no. 9, pp. 1186–1191, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus